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ss: 27630mrc@comb.esSummary The objective of the study was to evaluate the best method for
interpreting the bronchodilator test (BDT). Five formulas for expressing the BDT
results were analyzed and compared: changes experienced by maximum expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC) measured in milliliters, in
percentage with respect to the baseline, in percentage with respect to the
predicted, in percentage with respect to the possible, and in standardized residuals.
Ninety-eight chronic obstructive pulmonary disease (COPD) patients were submitted
to a respiratory function test on two different days. On each occasion three
spirometries were conducted: basal, post-placebo and post bronchodilator. As a gold
standard, a normality interval was defined using the variability experienced with the
placebo between the two days of the study. The best formulas according to their
sensitivity, specivity and area under receiver operating characteristic (ROC) curve
were the ‘‘standardized residuals’’, with a cut point of .3, and the ‘‘percentage with
respect to the predicted’’ with a cut point of 6%.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
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(M. Rodrı´guez-Carballeira).Introduction
Spirometry in chronic obstructive pulmonary dis-
ease (COPD) patients, conducted prior to and after
the administration of a bronchodilator (bronchodi-
lator test, BDT), not only is useful for diagnosis butd.
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Interpretation of the bronchodilator test in COPD 35also has therapeutic and prognostic implications.1–7
The possible association between bronchodilator
response and prognosis has not been elucidated:
some reviews emphasize that subjects who are
hyperresponsive have great diminution of lung
function,8,9 but recently the inhaled steroids in
obstructive lung disease in Europe (ISOLDE) study3
and Anthonisen et al.4 found that baseline bronch-
odilator response did not relate to the subsequent
decline in lung function. Therefore, the BDT is
normally performed in respiratory function labora-
tories for patients with COPD. However, this test
procedure and its interpretation have never been
standardized; there is no general agreement about
how to report results, or definitions of significant
positive response thresholds.10 To determine the
best reporting method,the following are required:I. The most appropriate parameter: The max-
imum expiratory volume in 1 s (FEV1) is the most
utilized, since it is considered to have greater
sensitivity to detect bronchoreversibility, smal-
ler variability and better reproducibility.11,12 In
a previous study, we analyzed FEV1, forced vital
capacity (FVC) and peak flow (PEF): FEV1 and
FVC showed the minor unexplained variability
and better reproducibility, clearly better than
PEF.13 So we decided to continue the study
considering the variation in both for the
interpretation of the BDT.II. The best way to express the change after
medication: Many formulas have been proposed
for expressing the bronchodilator response
(Table 1),1,14–17 but few publications have
compared these different methods, and those
comparisons are not comprehensive and are
done in heterogeneous groups of pa-
tients.15,16,18 Our group has analyzed the
reproducibility—by the calculation of the in-
traclass correlation coefficient—and the de-
pendency on the baseline—by the calculation of
the Pearson correlation coefficient—of the
formulas shown in Table 1. The best results
were obtained for the change expressed in
milliliters (ML), percentage with respect to the
predicted (PCP), percentage with respect to the
possible (%POSSIBLE), and standardized resi-
duals (SDR).13III. The placebo effect: The best way to evaluate
the BDT is to take spontaneous variability and
the placebo effect into account, with the goal
of delimiting a pharmacological effect.IV. The best threshold for determining the ex-
istence of significant bronchoreversibility (po-
sitive BDT): It is difficult to establish a threshold
because bronchodilation is a continuous, notdichotomous, variable.19 There have been
multiple proposals, but almost none are based
on controlled studies.2,14,20,21The aim of this study was to analyze the
sensitivity, specificity and area under the receiver
operating characteristic (ROC) curve and to deter-
mine the best cut point of differents formulas for
discriminating between significant and non-signifi-
cant bronchodilator responses in the BDT. The
formulas studied are the more reproducible and less
dependent on the baseline (ML, PCP, %POSSIBLE and
SDR), Furthermore, we included the PC because it is
most widely used in the clinical practice.Methods
The study included patients with COPD, defined by
clinical and spirometric criteria (regular coughing
and expectoration lasting more than 3months/year
during the last 2 years, FEV1o70% with respect to
the predicted, and FEV1/FVCo.70) who came to
our laboratory for a spirometry. The inclusion
criteria were that their bronchopathy was stable
(no decompensation in the previous 2 months), that
they gave their informed consent to participate in
the study and that the variation in their basal FEV1
between the two days of the study was less than
15% (as a spirometric criteria of stability). One
hundred and four COPD patients were studied on
two occasions, 7–14 days apart. On each day of the
study, a basal spirometry was conducted, another
30min after receiving two inhalations of placebo,
and a third 30min after receiving 1500 mg of
terbutaline. Bronchodilator treatment and caffeine
intake was suspended 12 h before the study. The
spirometries were performed using the European
Respiratory Society protocol.14 The medication was
administrated using a pressurized cartridge and a
750mL spacer device (NebuhalerR). A bell spiro-
metry was used (SensorMedicsR PEFT Horizon). The
‘back extrapolation’ method was considered for
determining the start of test. The values developed
by Roca et al.22 for the Mediterranean population
were taken as the reference values.
Statistical analysis
The formulas that showed better behavior with
regard to variability, reproducibility and depen-
dence on the basal value in the previous study
mentioned above13 were analyzed comparing their
sensitivity, specificity and area under the ROC
curve.
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Interpretation of the bronchodilator test in COPD 37We considered the ‘natural variability’ as the
standard deviation (SD) of the variation seen in the
spirometric indices after placebo administration
during both days of the study. Subsequently, the
Pearson’s correlation coefficient between this SD
and the mean basal FEV1 was determined to
analyze their relation with the basal value. The
result shows association between the ‘natural
variability’ of FEV1 and the grade of basal obstruc-
tion. So that to analyze the formulas with FEV1, the
patients were subdivided into three groups on the
basis of function of their basal FEV1: one group with
FEV1o 1000mL; the second with FEV1 between
1000 and 2000mL and the third with
FEV142000ml. In order to define a reference
standard for the interpretation of the BDT, we
calculated a normality interval (NI) for each group
of patients, according to their natural variability.Table 2 Spirometric basal characteristics of patients.
Parameter
Age mean yr (SD)
Male (%)
Smokers (continous and quitters)
FEV1(L)
FVC(L)
FEV1 (% predicted)
FVC (% predicted)
FEV1/FVC
Results expressed as mean (7SD).
Table 3 Definition of the normality interval.
Parameter Incre
place
Total patients with COPD (N ¼ 98)
FEV1 19
FVC 29
COPD patients with FEV1o1000mL (N ¼ 23)
FEV1 28
FVC 42
COPD patients with FEV1 1000–2000mL (N ¼ 65)
FEV1 10
FVC 21
COPD patients with FEV142000mL (N ¼ 10)
FEV1 46
FVC 45
Values are expressed in mL.
SDi: intrasubject standard deviation.This interval was calculated using the formula
proposed by Chinn.23 This formula uses the intra-
individual standard deviation obtained from a
repeated-measure model to create a reference
interval for changes. Thus, a threshold can be
defined, beyond which changes in FEV1 and FVC
may be attributed to a pharmacological effect. The
upper limit of the NI is the point from which the
changes experienced after the BD is due to a real
therapeutic effect (positive BDT).
The sensitivity and specificity of the different
methods for interpreting the BDT were calculated
taking the NI as a gold standard and their areas
under the ROC curve were compared. The area
under the curve was calculated using the Man-
n–Whitney U-test and its 95% confidence interval
from the standard error (SE) using the formula
proposed by Hanley and McNeil.24 The comparison1st day 2nd day
65 (10)
91 (93%)
96%
1.38 (7.48) 1.42 (7.48)
2.64 (7.68) 2.70 (7.69)
49 (15) 50 (15)
68 (14) 70 (14)
.52 (7.11) .52 (7.12)
ase with
bo
SDi Upper limit
of the NI
85 185
130 284
46 118
129 295
90 186
133 280
116 273
124 287
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M. Rodrı´guez-Carballeira et al.38among the best curves was made applying a Z-test
according to the method proposed by Hanley and
McNeil.25
In order to determine the best cut point for
discriminating between positive and negative re-
sponses to the bronchodilator multiple correlative
points were tested, with sensitivity and specificity
calculated for each.
The data were analyzed using the SPSS-PC
statistical package (version 8.0).Changes of FVC with the BDT
Specificity
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Figure 1 ROC curves of the different formules to express
the changes experienced by FEV1 and FVC with the
bronchodilator test.Results
Of the 104 patients included, four were excluded
because they did not complete the study and two
more because they did not meet the stability
criteria. The description of the baseline and
spirometric characteristics of the 98 patients who
were included in the study appears in Table 2.
Upon analyzing the relation between the natural
variability and the basal value, no relationship was
detected when analyzing FVC, but a significant
association was detected in the case of FEV1
(r ¼ :37, P ¼ :0001). Thus, we calculated an NI
after applying the formula suggested by Chinn both
to the group of patients with COPD and to the three
subgroups in the sample, defined by their basal
FEV1, in order to get more homogeneous groups.
Table 3 shows the variation in FEV1 and FVC
experienced with placebo, and the resulting NI in
each case. The upper limit of the NI defined for FVC
varies only slightly in relation to basal FEV1. In the
case of FEV1, it increases with basal FEV1, accord-
ing to the analysis of natural variability described in
the previous section. For this reason, we decided to
utilize the threshold given by the NI of each
subgroup of patients as a reference standard. For
FVC we used the same threshold for all COPD
patients.
Considering this standard of reference, of the
196 BDT performed, 65 (33%) were positive accord-
ing to the FVC criteria of significant bronchorever-
sibility, 84 (43%) were positive according to the
FEV1 criteria of significant bronchoreversibility and
49 (25%) were positive according to both criteria.
Considering one or both criteria 98 (50%) of BDT
were positive.
We compared the three best methods for
expressing the BDT based on their reproducibility
and dependency on the baseline: %POSSIBLE, PCP
and SDR. Changes measured in milliliters (ML) were
excluded from the comparison, since in the
Methods section it was shown that when FEV1 is
used, the threshold should depend on the basal
FEV1. On the other hand, since this system ofmeasure is used to define the reference standard,
the comparison could be biased. When measuring
both FEV1 and FVC, the ROC curves defined for each
of the interpretation methods showed a greater
area and a narrower confidence interval for the
SDR, followed by the PCP, both clearly superior to
the %POSSIBLE (Fig. 1). When comparing these two
curves, SDR was significantly superior (Po:05).
Upon analyzing the results in the three defined
COPD subgroups, differences were not seen with
regard to those systems that had the best inter-
pretations (Table 4). Only the %POSSIBLE when
measuring FVC deviates from this rule, since the
area diminishes significantly in the FEV142 L group.
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Table 4 Sensitivity and specificity of different methods for interpreting the bronchoditlator test.
Group parameter Threshold Sensitivity Specificity Area under ROC
curve (CI 95%)
All
FEVPCP 6% 82.7 89.0 .92 (.89–.95)
FEVPOS 10% 82.7 75.5 .87 (.82–.92)
FEVSDR .3SDR 89.8 80.6 .94 (.92–.96)
FEVPC 12 81.6 84.7 .79 (.70–.88)
FVCPCP 6% 75.0 86.0 .88 (.80–.92)
FVCPOS 15% 83.7 79.6 .86 (.80–.92)
FVCSDR .3SDR 83.7 76.5 .90 (.86–.94)
FVCPC 5 83.7 67.3 .89 (.85–.93)
FEV1(o1 L)
FEVPCP 4% 96.4 93.3 .96 (.94–.98)
FEVPOS 6% 96.4 93.3 .96 (.94–.98)
FEVSDR .3SDR 92.9 100 .96 (.94–.98)
FEVPC 13 96.4 86.7 .95 (.93–.97)
FVCPCP 4% 92.9 93.3 .96 (.94–.98)
FVCPOS 10% 92.9 86.7 .97 (.95–.99)
FVCSDR .3SDR 89.3 80.0 .94 (.91–.97)
FVCPC 5 96.4 60.0 .94 (.91–.97)
FEV1(1–2 L)
FEVPCP 6% 80.0 92.1 .92 (.89–.95)
FEVPOS 10% 85.0 79.0 .88 (.83–.93)
FEVSDR .3SDR 86.2 81.0 .92 (.89–.95)
FEVPC 12 80.0 92.1 .90 (.86–.94)
FVCPCP 4% 81.5 74.6 .89 (.85–.93)
FVCPOS 15% 84.6 76.2 .98 (.97–.99)
FVCSDR .3SDR 83.1 77.8 .91 (.88–.94)
FVCPC 5 83.1 71.4 .87 (.82–.92)
FEV1(42 L)
FEVPCP 6% 100 85.7 .98 (.95–1)
FEVPOS 18% 100 85.7 .96 (.92–1)
FEVSDR .3SDR 100 71.4 .99 (.97–1)
FEVPC 12 87.5 100 .99 (.97–1)
FVCPCP 5% 75.5 93.0 .90 (.84–.96)
FVCPOS 15% 75.0 92.9 .76 (.64–.88)
FVCSDR .3SDR 75.5 93.0 .90 (.84–.96)
FVCPC 5 75.0 92.9 .88 (.81–.95)
FEV1: maximum expiratory flow in 1 s; FVC: forced vital capacity; FEVPCP: percentage with respect to the predicted value of the
FEV1; FVCPCP: percentage with respect to the predicted value of the FVC; FEVPOS: percentage with respect to the possible
value of the FEV1; FVCPOS: percentage with respect to the possible value of the FVC; FEVSDR: standardized residuals of FEV1;
FVCSDR: standardized residuals of FVC; FEVPC: percentage with respect to the baseline of the FEV1; FVCPC: percentage with
respect to the baseline FVC.
Interpretation of the bronchodilator test in COPD 39In clinical practice, the most used formula
to express the result of the BDT is the percentage
of the baseline (PC), so we decided to analyze its
ROC curve. Considering all patients, when measur-
ing the changes of FEV1 the area of the ROC curve
was .79, the cut off 12% with a sensitivity of 81.6
and specificity of 84.7. When measuring the
changes of FVC, the area of the ROC curve was
.89, the cut off 5% with a sensitibity of 84 and
specificity of 67.We observe that the most adequate significance
thresholds for interpreting the response to the BDT,
taking the NI of each subgroup as a reference, are
very similar for both the FEV1 and the FVC and that
they remain practically constant (Table 4). The only
exception is in the case of %POSSIBLE: it is observed
that the best threshold obtained increases with
basal FEV1, on applying this formula to the change
of FVC and although more so in the case of FEV1, in
each patient subgroup (Fig. 2).
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Figure 2 Change experienced by FEV1 and the FVC after
the bronchodilator expressed in percentage with respect
to possible (%POSSIBLE) for basal FEV1 (L).
M. Rodrı´guez-Carballeira et al.40Discussion
The lack of unanimity in the interpretation of the
BDT was the principal reason for the present
study—to analyze the different interpretation
formulas proposed and attempt to determine which
are the most adequate. We have compared their
capacity to discriminate between positive and
negative responses to the bronchodilator and we
also have analyzed the best cut points. According
to their reproducibility, variability and area
under ROC curve, the best are PCP and SRS with a
cut point of 6% and .3, respectively, for both FEV1
and FVC.
The main problem for interpreting the BDT
derives from the large spontaneous variability
presented by the bronchodilator response. Ker-
stjens et al.18 observed that only 42% of the
patients showed a consistent classification in their
acute response to the bronchodilator during several
years of follow-up. In this same vein, Anthonisenand Wright6 upon following 985 patients with COPD
for several years observed that up to 70% of the
patients had variable bronchodilator responses.
The reference standard for assessing whether or
not the BDT response is significant should take this
variability into account and also the possible
placebo effect. Some authors attempted to survey
the natural variability of spirometric indices using
confidence intervals based on the variation of these
parameters.26–28 In our study, repeated measures
have enabled us to analyze the intraindividual
variability, while adding the placebo has enabled us
to measure its influence as well. In order to
measure both the intraindividual variability and
the placebo effect we apply the formula proposed
by Chinn23 to the placebo response. Due to a direct
association detected between the degree of basal
obstruction and the natural variability experienced
by FEV1, we define a specific threshold for each
subgroup of patients according to their basal
obstruction. It must be pointed out that these
results contrast with those of Tweeddale et al.26
who did not find a relationship between basal FEV1
and changes in its absolute value. They proposed a
single significance threshold, applicable to all
patients, regardless of their basal FEV1.
The area under the ROC curve makes it possible
to compare the different systems, and interpret
the changes that the bronchodilator causes in FEV1
and FVC. The best ways of expressing the BDT are
the SDR and the PCP, both of which have a larger
area under the ROC curve and narrower confidence
intervals. %POSSIBLE shows a worse result in this
analysis by having a smaller area under the ROC
curve, and less specificity and accuracy. Upon
analyzing the behavior of %POSSIBLE, it is impor-
tant to point out that the best threshold for
identifying a positive BDT varies with regard to
the degree of basal obstruction, in the case of both
FEV1 and FVC, something that does not happen with
the other two formulas, which present constant
significance thresholds (Table 4). This variation of
%POSSIBLE may be because it exaggerates the
responses of patients with smaller degrees of
obstruction (Fig. 1). This behavior allows us to
prefer PCP and SDR. These results partially contra-
dict the conclusions of Dompeling et al.16 who
compare six different formulas for expressing the
BDT based on the increase in FEV1, and settle on
%POSSIBLE and the %ACHIEVABLE. However, it is
necessary to point out that this decision is
exclusively based on an analysis of reproducibility
and dependency on the baseline value.
The area under ROC curve for PC was minor than
that of SDR and PCP, moreover it has less
reproducibility and more dependency on the
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Interpretation of the bronchodilator test in COPD 41baseline value, age, sex and height, so we prefer
PCP or RSD.
SDR is the other clearly useful formula according
to our results. Other works have shown evidence
that they take into account the range of reference
values, that they have the same scale for different
parameters and, in addition, that they do not
depend on age, sex or height.17–19
There is no unanimity of opinion or evidence
based on contrasted studies for the adequacy of
significant thresholds used to interpret the differ-
ent formulas of expressing the bronchodilator
response.5,11,18,29,30 Few attempts have been car-
ried out in order to unify criteria on the basis of
scientific studies. Tweeddale et al.26 used con-
fidence intervals—which attempt to delimit natur-
al variability—to extract significance limits for
FEV1 and FVC. However, he did not consider either
the placebo effect or intraindividual variability.
In conclusion, to interpret the BDT in patients
with COPD, changes in FEV1 and FVC should be
considered. If the absolute value is used, the
threshold with FVC should be 300mL, regardless
of the degree of basal obstruction. For FEV1, the
significant threshold depends on the basal FEV1:
118mL for basal FEV1o1000mL, 186mL for basal
FEV1 between 1000 and 2000mL, and 273mL for
basal FEV142000mL. The most precise formulas
for interpreting changes in FEV1 and FVC are SDR
and PCP. An increase greater than .3 should be
considered significant in the case of SDR and
greater than 6% in the case of PCP.References
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